A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM).

Trial Profile

A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms MAPS
  • Most Recent Events

    • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 09 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 23 Dec 2015 Results published in the Lancet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top